Uthoff H, Staub D, Socrates T, Meyerhans A, Bundi B, Schmid H P, Frauchiger B
Department of Angiology, University Hospital, Basel, Switzerland.
Vasa. 2010 Nov;39(4):325-33. doi: 10.1024/0301-1526/a000057.
The predictive value of PROCAM, FRAMINGHAM, SCORE and SMART-score to estimate the cardiovascular risk in patients with overt atherosclerosis had never been assessed.
96 consecutive patients with clinically evident atherosclerosis (coronary, cerebrovascular, peripheral artery and renovascular disease) were enrolled in this preliminary observational study. At baseline, medical history and blood chemistry were obtained. Sonographic measurement of the intima-media thickness (IMT) in the common carotid artery was performed and risk estimations according to the above listed risk scores were calculated. During a 6 year follow-up the occurrence of cardiovascular death, acute coronary syndrome and stroke was assessed.
Mean (±SD) risk-scores were 10.9±2.5, range 6-17 (SMART); 18.9±18.2%; range 0.2-94.1% (PROCAM); 21.4±13.1%, range 4-56% (FRAMINGHAM); and 4.8±3.9%, range 0.4-15.3% (SCORE). Mean IMT was 0.84±0.14 mm, range 0.51-1.20 mm. All scores correlate significantly with each other (r>0.321; p<0.01), but only SMART-score correlated significantly with baseline IMT(r=0.372; p<0.001). Within the median follow-up of 73 months, a cardiovascular endpoint was observed in 36 (42%) patients. The AUC (95% confidence interval) for SMART-risk-score predicting a cardiovascular event was 0.67 (0.54-0.77; p<0.02); for PROCAM 0.60 (0.47-0.73; p=n.s.); for FRAMINGHAM 0.56 (0.43-0.69; p=n.s.); and for SCORE 0.60 (0.46-0.73; p=n.s.). Cox regression analysis showed a relative risk for a cardiovascular event per additional SMART score point of 1.15 (95% CI 1.01-1.30 p=0.03).
PROCAM-, FRAMINGHAM- and SCORE-risk score seem to be barely useful in a secondary prevention setting. In patients with overt atherosclerosis, the cardiovascular risk seems to be better assessed by means of the SMART score.
从未评估过PROCAM、弗雷明汉(FRAMINGHAM)、SCORE和SMART评分对明显动脉粥样硬化患者心血管风险的预测价值。
96例有临床明显动脉粥样硬化(冠状动脉、脑血管、外周动脉和肾血管疾病)的连续患者纳入了这项初步观察性研究。在基线时,获取病史和血液化学指标。对颈总动脉进行内膜中层厚度(IMT)的超声测量,并根据上述风险评分计算风险估计值。在6年随访期间,评估心血管死亡、急性冠状动脉综合征和中风的发生情况。
平均(±标准差)风险评分分别为:SMART评分为10.9±2.5,范围6 - 17;PROCAM评分为18.9±18.2%,范围0.2 - 94.1%;弗雷明汉评分为21.4±13.1%,范围4 - 56%;SCORE评分为4.8±3.9%,范围0.4 -
15.3%。平均IMT为0.84±0.14mm,范围0.51 - 1.20mm。所有评分之间均显著相关(r>0.321;p<0.01),但只有SMART评分与基线IMT显著相关(r = 0.372;p<0.001)。在73个月的中位随访期内,36例(42%)患者出现心血管终点事件。SMART风险评分预测心血管事件的曲线下面积(95%置信区间)为0.67(0.54 - 0.77;p<0.02);PROCAM为0.60(0.47 - 0.73;p = 无统计学意义);弗雷明汉为0.56(0.43 - 0.69;p = 无统计学意义);SCORE为0.60(0.46 - 0.73;p = 无统计学意义)。Cox回归分析显示,每增加一个SMART评分点,心血管事件的相对风险为1.15(95%置信区间1.01 - 1.30;p = 0.03)。
在二级预防环境中,PROCAM、弗雷明汉和SCORE风险评分似乎几乎没有用处。在明显动脉粥样硬化患者中,通过SMART评分评估心血管风险似乎更好。